文献速递新发突发、热带与寄生虫病

CYP2D6基因型对美军人群伯氨喹代谢的影响

Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
PubMed 文献 · J Infect Dis · 2019-01-01

该研究在550名美军人员中测定CYP2D6基因型与表型,并在45名志愿者中测量30mg口服伯氨喹的药代动力学。结果显示,正常代谢型者伯氨喹血浆暴露较低,且尿中检出5,6-邻醌,提示CYP2D6在伯氨喹活化中起关键作用。

要点

  • CYP2D6中间代谢型和慢代谢型者伯氨喹血浆药代动力学暴露较正常代谢型者降低。
  • 5,6-邻醌几乎仅在正常代谢型者尿中检出,支持CYP2D6在伯氨喹活化中的作用。
  • 间日疟根治使用伯氨喹时,CYP2D6表型可能影响疗效,需关注代谢低下人群。

核心结论

  • CYP2D6中间代谢型和慢代谢型者伯氨喹血浆药代动力学暴露较正常代谢型者降低。
  • 5,6-邻醌几乎仅在正常代谢型者尿中检出,为CYP2D6参与伯氨喹根治提供进一步证据。

研究设计与样本

  • 研究测定了550名服役人员的CYP2D6基因型与表型。
  • 在45名志愿者中测量了30mg口服伯氨喹的药代动力学。
  • 采用超高效液相色谱-质谱法测定血浆和尿中伯氨喹及其代谢物。

主要发现

  • 515名可预测单一表型者中,58%为正常代谢型,35%为中间代谢型,5%为慢代谢型,2%为超快代谢型。
  • 正常代谢型者伯氨喹从0到∞的血浆浓度时间曲线下面积中位数低于中间代谢型或慢代谢型者。
  • 所有正常代谢型者尿中检出新型5,6-邻醌,但血浆中未检出。

临床怎么用

  • 间日疟根治使用伯氨喹时,可考虑CYP2D6表型对伯氨喹活化及疗效的潜在影响。
  • 对中间代谢型或慢代谢型者,需关注伯氨喹代谢降低可能带来的根治失败风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasmodium vivax malaria requires a 2-week course of primaquine (PQ) for radical cure. Evidence suggests that the hepatic isoenzyme cytochrome P450 2D6 (CYP2D6) is the key enzyme required to convert PQ into its active metabolite. METHODS: CYP2D6 genotypes and phenotypes of 550 service personnel were determined, and the pharmacokinetics (PK) of a 30-mg oral dose of PQ was measured in 45 volunteers. Blood and urine samples were collected, with PQ and metabolites were measured using ultraperformance liquid chromatography with mass spectrometry. RESULTS: Seventy-six CYP2D6 genotypes were characterized for 530 service personnel. Of the 515 personnel for whom a single phenotype was predicted, 58% had a normal metabolizer (NM) phenotype, 35% had an intermediate metabolizer (IM) phenotype, 5% had a poor metabolizer (PM) phenotype, and 2% had an ultrametabolizer phenotype. The median PQ area under the concentration time curve from 0 to ∞ was lower for the NM phenotype as compared to the IM or PM phenotypes. The novel 5,6-ortho-quinone was detected in urine but not plasma from all personnel with the NM phenotype. CONCLUSION: The plasma PK profile suggests PQ metabolism is decreased in personnel with the IM or PM phenotypes as compared to those with the NM phenotype. The finding of 5,6-ortho-quinone, the stable surrogate for the unstable 5-hydroxyprimaquine metabolite, almost exclusively in personnel with the NM phenotype, compared with sporadic or no production in those with the IM or PM phenotypes, provides further evidence for the role of CYP2D6 in radical cure. CLINICAL TRIALS REGISTRATION: NCT02960568.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Spring MD, Sousa JC, Li Q, et al. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population. J Infect Dis. 2019. PMID: 31549155. doi:10.1093/infdis/jiz386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。